News

26/03/15

Update on the project to combine STALLERGENES and GREER LABORATORIES

30/03/15
Stallergenes announces the approval in Japan of STG320, the first sublingual immunotherapy tablet for the treatment of house dust mite allergy

STG320 is the first house dust mite immunotherapy tablet ever to obtain a...

[more]
03/03/15
2.5% growth in net sales & EBITA outperformed 2014 targets

• Positive performance for all routes of administration

• Strong growth...

[more]

Follow us on :

STALLERGENES, A GLOBAL ALLERGY PLAYER


Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. 

Stallergenes’ comprehensive approach to allergic diseases includes a complete portfolio combining diagnosis products and treatments and a new generation of allergen immunotherapy treatments.